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A B S T R A C T
Proteasome inhibitors have a 20 year history in cancer therapy. The ﬁrst proteasome inhibitor,
bortezomib (Velcade, PS-341), a break-through multiple myeloma treatment, moved rapidly through
development from bench in 1994 to ﬁrst approval in 2003. Bortezomib is a reversible boronic acid
inhibitor of the chymotrypsin-like activity of the proteasome. Next generation proteasome inhibitors
include carﬁlzomib and oprozomib which are irreversible epoxyketone proteasome inhibitors; and
ixazomib and delanzomib which are reversible boronic acid proteasome inhibitors. Two proteasome
inhibitors, bortezomib and carﬁlzomib are FDA approved drugs and ixazomib and oprozomib are in late
stage clinical trials. All of the agents are potent cytotoxics. The disease focus for all the proteasome
inhibitors is multiple myeloma. This focus arose from clinical observations made in bortezomib early
clinical trials. Later preclinical studies conﬁrmed that multiple myeloma cells were indeed more
sensitive to proteasome inhibitors than other tumor cell types. The discovery and development of the
proteasome inhibitor class of anticancer agents has progressed through a classic route of serendipity and
scientiﬁc investigation. These agents are continuing to have a major impact in their treatment of
hematologic malignancies and are beginning to be explored as potential treatment agent for non-cancer
indications.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The incorporation of the ﬁrst proteasome inhibitor, bortezomib,
into anti-myeloma armamentarium can be considered a major
milestone in treatment of multiple myeloma, greatly improving
the response rates and overall survival in front-line and relapsed/
refractory settings. Although present in all cells, proteasomes are
relatively abundant in multiple myeloma cells making that disease
a target for proteasome inhibitors.
1.1. The proteasome
Protein activity regulation by synthesis and degradation
maintains cellular metabolic integrity and proliferation. The
proteasome, a multimeric protease complex, is central to cellular
protein regulation by degrading many proteins, thus activating
some pathways and shutting down others [1]. Proteins conjugated
to multiple units of the polypeptide ubiquitin are degraded by the* Corresponding author at: DCTD, National Cancer Institute, RM 4-W602, MSC
9735, 9609 Medical Center Drive, Bethesda, MD 20892, United States.
Tel.: +1 240 276 5972; fax: +1 240 276 7895.
E-mail addresses: Beverly.Teicher@nih.gov, teicherba@mail.nih.gov
(B.A. Teicher).
http://dx.doi.org/10.1016/j.bcp.2015.04.008
0006-2952/Published by Elsevier Inc. This is an open access article under the CC BY-Nproteasome [2–4]. Timed degradation/recycling of proteins is
essential for viability. The proteasome catabolizes intracellular
proteins thus controlling the intracellular proteins levels to
maintain cellular function [5–7]. Malignant cells are more
dependent upon the proteasome to remove mis-folded or damaged
proteins due to their genetic instability and rapid proliferation.
Accumulation of ubiquitinated proteins and/or mis-folded can
proteins lead to apoptosis. Proteins involved in cell division,
proliferation and apoptosis are substrates for the ubiquitin–
proteasome pathway as are mis-folded and mutated proteins.
Proteasomes are abundant and are located in the cytoplasm and
nuclei and of cells. The proteasome refers to the 26S proteasome
and includes a 20S core catalytic complex with 19S regulatory
subunits on each end (Fig. 1). Proteasomes enter the nucleus
through pores or post mitosis during development of the nuclear
envelope. Proteasome-mediated degradation proteins is enabled
by conjugation to multiple ubiquitin units. Ubiquitin is a 76-amino
acid protein. Ubiquitin is covalently linked to proteins by an
enzymatic reaction requiring Ub-activating (E1), Ub-conjugating
(E2) and Ub-ligating (E3) enzymes acting sequentially [7]. More
than four ubiquitin units must be linked to the target protein for
proteasome degradation [8]. The S19 regulatory particle guides
ubiquitinated proteins into the 20S particle. The 20S core complex
houses the proteolytic chamber. The 20S complex includes fourC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Illustration of the structure and function of the proteasome. Proteins to be degraded are conjugated with multiple units of ubiqutin then fed in to the proteasome
regulatory particle. The proteins are degraded to peptides by three protease functions in the b subunits of the core particle. The products are free ubiqutin units and peptide
fragments.
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speciﬁcally caspase-like (C-L), trypsin-like (T-L) and chymotryp-
sin-like (CT-L) catalytic proteases. The products produced by the
proteasome are 3–22 amino acid peptides and free ubiquitin
protein units (Fig. 1) [9].
Early in the study of the proteasome as a potential therapeutic
target, synthetic and natural product inhibitors of the proteasome
were identiﬁed [2,9]. Widely studied inhibitors included: lacta-
cystin, a streptomyces metabolite, which is metabolized to
lactacystin b-lactone, the active proteasome inhibitor [9–12];
peptide aldehydes, such as carbobenzoxyl-leucinyl-leucinyl-leuc-
inal-H (MG-132); boronic acid peptides [9,13]; and others
[13,14]. Dipeptide boronic acid derivatives, potent proteasome
inhibitors, could be administered to mice, and some were orally
bioavailable and relatively stable under physiological conditions
[9,15]. Boronic acid peptides were known to inhibit serine
proteases [16–18], whereas the dipeptide boronates had a high
degree of selectivity for the proteasome and were not potent
inhibitors of many common proteases.
Critical to the clinical development of proteasome inhibitors
was establishing a pharmacodynamic assay which measured the
potency and duration of inhibition of the proteasomes in normal
blood cells. In animal-model studies, the dipeptide boronic acid,
PS-341, rapidly disappeared from the vascular compartment
[19]. An accurate pharmacodynamic assay was developed to
supplement pharmacokinetic measurements. Both the chymo-
tryptic and tryptic activities of the proteasome could be detected
using ﬂuorogenic kinetic assays. These ﬂuorogenic kinetic assays
were optimized for both whole blood and blood cells. A method for
calculating percent inhibition from the ratio of the enzymatic
activities and knowledge of the catalytic mechanism of the
proteasome was developed using two structurally unrelated
inhibitors (PS-341 and lactacystin). The 20S proteasome concen-
tration in whole blood and red blood cells was equivalent, thus,
data collected from either source provided similar proteasome
inhibition. Cellular response to PS-341 was shown to be due to the
drug availability rather than cellular proteasome concentration.
PS-341 rapidly disappeared from the intravascular compartment
and distributed widely. Serum concentrations approached the
limit of pharmacokinetic detection within 1 h. The pharmacoki-
netic measurements were not sensitive enough to guide dosing for
PS-341, however, the pharmacodynamic assay measuring the
percentage of inhibition of proteasome function could be used toprovide a more biologically relevant characterization of drug
action. In early clinical trials, blood samples were collected before
therapy, and then 1, 6, and 24 h after each PS-341 dose for
pharmacodynamic proteasome activity determination. This assay
provided guidance regarding PS-341 doses near the safe limit of
proteasome inhibition which was 80% [19,20].
1.2. Multiple myeloma genetics
Multiple myeloma is divided into two main types: hyperdiploid,
with multiple trisomies of odd-numbered chromosomes, and
nonhyperdiploid, with recurrent immunoglobulin heavy chain gene
translocations. Multiple myeloma progression is associated with
MYC rearrangements, the most common multiple myeloma
mutation, present in about 50% of patients. Multiple myeloma
presents with marked subclonal heterogeneity that poses a major
challenge to successful disease control. In 1996, Bergsagel et al. [21]
described IGH translocations involving seven partners with break-
points in three B-cell-speciﬁc DNA modiﬁcation processes occur at
early stages of multiple myeloma pathogenesis [21]. By contrast,
MYC:IGH rearrangements, generally do not have these IGH break-
points in the three B-cell-speciﬁc DNA modiﬁcation processes that
are inactivated in plasma cells or plasma cell tumors. In multiple
myeloma MYC rearrangements, often combinations of transloca-
tions, insertions, deletions and inversions, were thought to be late
events, not involving immunoglobulin genes. However, MYC over-
expression can cause progression to multiple myeloma in a
monoclonal gammopathy of undetermined signiﬁcance (MGUS)-
prone mouse strain, as a model for human multiple myeloma.
Multiple myeloma genetic rearrangements can reposition MYC near
a number of conventional enhancers, and often genes with super-
enhancers. Multiple myeloma lacking MYC rearrangement have
MYC expression at higher levels than in MGUS. However, germinal
center MYC activation did not cause multiple myeloma in a mouse
strain that rarely develops MGUS. MYC rearrangements contribute
to multiple myeloma autonomy [22].
Massively parallel sequencing of paired tumor/normal samples
from 203 multiple myeloma specimens identiﬁed mutated genes,
copy number alterations and putative tumor suppressor genes
based on homozygous deletions and loss of heterozygosity. KRAS
mutations were seen frequently in previously treated patients, as
were NRAS, BRAF, FAM46C, TP53, and DIS3 mutations. Mutations
were present in subclonal populations, and multiple mutations in
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hyperdiploid changes appear to be early or even initiating
mutagenic events that are followed by additional aberrations
including copy number abnormalities, translocations, mutations,
and epigenetic modiﬁcations leading to plasma cell immortaliza-
tion and disease progression [24].
2. Bortezomib
In 1993, Alfred Goldberg, the discoverer of the proteasome,
and colleagues founded the company MyoGenetics to developBortezomib (PS-341)
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Table 1
Characteristics of proteasome inhibitors including chemical class, potency in inhibiting proteasome protease activities, and clinical circulating half-life and major route of
administration.
Active moiety Binding CT-L IC50
(nM)
C-L IC50
(nM)
T-L IC50
(nM)
Circulating
half-life (min)
Route Refs.
Bortezomib (PS-341) Boronate Reversible 7.9  0.5 53  10 590  67 110 Intravenous [59]
Carﬁlzomib (PR-171) Epoxyketone Irreversible <5 2400 3600 <30 Intravenous [60]
Marizomib (NPI-0052) b-Lactone Irreversible 3.5  0.3 430  34 28  2 10–15 Intravenous [61]
Ixazomib (MLN9708) Boronate Reversible 3.4 31 3500 18 Oral [59,61]
Oprozomib (ONX0912) Epoxyketone Irreversible 36–82 ND ND 30–90 Oral [63,64]
Delanzomib (CEP-18770) Boronate Reversible 3.8 ND ND ND Oral [51]
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producing an IC90 of 0.05 mM after 24 h exposure. PS-341 was
potently cytotoxic when administered to mice bearing EMT-6
tumors. PS-341 was also toxic to bone marrow CFU-GM from the
femurs of the same mice. PS-341 increased the tumor cell killing of
radiation therapy, cyclophosphamide, and cisplatin in mice
bearing EMT-6 tumors. In tumor growth delay assays, PS-341
had antitumor activity against primary Lewis lung carcinoma as
well as against spontaneous lung metastases in the same mice. In
combination, with 5-ﬂuorouracil, cisplatin, paclitaxel and doxoru-
bicin, PS-341 produced additive tumor growth delays against
subcutaneous primary tumors and was highly effective against
disease metastatic to the lungs [6].
In 1995, PS-341 (NSC681239) along with several analogs (NSCs:
681226, 681228, 681229, 681231, 681234, 68236, and 681237),
was submitted to the NCI-60 cell line screen and was found to have
potent, wide-ranging activity in solid and liquid tumor cell lines
(http://dtp.nci.nih.gov). There was good correlation between
proteasome inhibition and cell line response among tested
compounds. PS-341 produced a unique pattern in the COMPARE
analysis, suggesting that PS-341 had a novel mechanism of action.
PS-341 had antitumor activity in several human solid tumor
xenografts [25].
In 1996, nuclear factor kB (NF-kB) activity was recognized as a
pro-tumor cell survival protein in multiple myeloma. Normally,
the function of NF-kB is inhibited by binding to the inhibitor, IkB.
Release of activated NF-kB occurs after proteasome-mediated
degradation of ubiqutin-conjugated IkB. Thus, PS-341 indirectly
inhibited activation of NF-kB. PS-341 was cytotoxic toward four
murine and two human squamous cell carcinoma cell lines via
apoptosis. PS-341 inhibited growth of murine and human
squamous cell carcinoma tumors in mice at doses of 1–2 mg/kg
(3–6 mg/m2) given three times weekly [25]. Multiple myeloma
cells have increased NF-kB activity compared with normal
hematopoietic cells. PS-341 blocked nuclear translocation of NF-
kB, and demonstrated antitumor activity against chemo-resistant
and chemo-sensitive multiple myeloma cells alone and in models
of the bone marrow microenvironment both in vitro and in vivo
multiple myeloma xenografts. The sensitivity of chemo-resistant
myeloma cells to chemotherapeutic agents was increased when
combined with PS-341 [4]. Ma et al. [26] showed that PS-341
inhibited proliferation and induced cell death in human multiple
myeloma cell lines and freshly isolated multiple myeloma clinical
samples; inhibited MAP kinase signaling in multiple myeloma
cells; caused apoptosis in p53 wild-type and p53 mutant multiple
myeloma cells; overcame drug resistance; increased dexametha-
sone anti-multiple myeloma activity; and overcame the protection
from apoptosis in multiple myeloma cells by interleukin-6. PS-341
inhibited multiple myeloma cells growth by decreasing adherence
to bone marrow stromal cells and NF-kB-dependent interleukin-6
production. PS-341 acted both on multiple myeloma cells and on
cellular interactions and cytokine secretion in the bone marrow
milieu to block tumor cell growth, cause apoptosis, and overcome
drug resistance [27]. Gene expression proﬁling indicated that themolecular consequences of PS-341 exposure in multiple myeloma
cells showed down-regulation of growth/survival signaling path-
ways, and up-regulation of molecules involved in pro-apoptotic
pathways consistent with proteasome inhibition, as well as up-
regulation of heat-shock proteins and ubiquitin/proteasome
pathway proteins consistent with stress responses [28]. Sub-
cytotoxic PS-341 concentrations sensitized multiple myeloma
lines and patient cells to DNA-damaging chemotherapeutic drugs
including doxorubicin and melphalan. Sensitization was observed
in cells resistant to DNA-damaging drugs and cells isolated from a
patient who relapsed after PS-341 monotherapy. PS-341 complete-
ly blocked cell adhesion-mediated drug resistance. As determined
by gene expression proﬁling and proteomic analysis, PS-341 down-
regulated the expression of effectors involved in cellular response
to genotoxic stress. The data indicate that PS-341 down-regulated
apoptosis inhibitors expression, and inhibited genotoxic stress
response pathways, thus, increasing sensitivity to DNA-damaging
chemotherapeutic drugs [29].
ProScript was acquired by Millennium Pharmaceuticals in 1999
(Fig. 2). Critical to enabling the clinical development of PS-341 was
the creation of a suitable clinical formulation of stable composition
that released the boronic acid compound in aqueous media
[30]. The clinical formulation and preclinical safety testing of PS-
341 with this formulation was carried out by the Developmental
Therapeutics Program of the National Cancer Institute. Several
Phase 1 clinical trials were conducted with bortezomib varying the
dosing schedule and patient groups. A breakthrough Phase
1 clinical trial determined the maximum-tolerated dose (MTD),
dose-limiting toxicity (DLT), and pharmacodynamics of bortezo-
mib in patients with refractory hematologic malignancies
[32]. Patients were treated with PS-341 2-times per week for
4 weeks at doses ranging from 0.40 to 1.38 mg/m2 followed by a 2-
week rest. PS-341 pharmacodynamics was evaluated by measure-
ment of whole blood 20S proteasome activity [19,31]. Twenty-
seven patients received 293 PS-341 doses comprising 24 complete
cycles. Dose limiting toxicities occurred at doses greater than
1.04 mg/m2 included fatigue, thrombocytopenia, hyponatremia,
hypokalemia, and malaise. PS-341 caused 20S proteasome
inhibition in a time-dependent manner, and percent proteasome
inhibition was related to PS-341 dose. Among the 9 assessable
patients with heavily pretreated plasma cell malignancies
completing one cycle of therapy, there was one complete response
(CR) and a reduction in paraprotein and/or marrow plasmacytosis
in 8 others. A mantle cell lymphoma patient and a follicular
lymphoma patient had shrinkage of nodal disease. PS-341 was
well-tolerated at 1.04 mg/m2 on the twice weekly i.v. bolus for
2 weeks, followed by a 1-week recovery period schedule. Thus, PS-
341 was clinically active against refractory multiple myeloma and
possibly non-Hodgkin’s lymphoma [32]. In 2002, a second Phase
1 clinical trial evaluated the toxicity and pharmacodynamic
behavior of PS-341 administered 2-times per week by intravenous
bolus injection for 2 weeks, followed by a 1 week recovery period
in patients with advanced solid tumor malignancies [31]. In this
Phase 1 trial, 43 patients were treated with PS-341 at doses ranging
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dynamic studies were performed to determine 20S proteasome
activity. PS-341 dose-limiting toxicities in this trial were diarrhea
and sensory neurotoxicity. There was no dose-limiting hemato-
logical toxicity. A PS-341 dose related inhibition of 20S proteasome
activity was documented. A patient with refractory non-small cell
lung carcinoma had a one major clinical response. The dose of
1.04 mg/m2/dose administered twice weekly for 4 weeks followed
by a 2-week rest, was recommended for Phase 2 trials [31].
These Phase 1 clinical trials, along with preclinical ﬁndings of
anti-myeloma activity, provided the impetus for a multicenter,
open-label, non-randomized Phase 2 bortezomib clinical trial for
relapsed, refractory multiple myeloma treatment. The Phase 2 trial
reported in 2003 enrolled 202 patients. Patients received 1.3 mg of
bortezomib/m2 2-times per week for 2 weeks, followed by 1 week
without treatment, for up to 8 cycles. In some patients, oral
dexamethasone (20 mg) was added to the regimen on the day of
and the day after bortezomib administration. Response was
evaluated according to the European Group for Blood and Marrow
Transplantation criteria and by an independent review committee.
Of 193 evaluable patients, 92% were previously treated with three
or more agents for myeloma, and 91% of patients were refractory to
the most recent therapy. The response rate to bortezomib was
35%, including 7 patients in whom myeloma protein became
undetectable and 12 patients with myeloma protein detectable
only by immunoﬁxation. The median overall survival was
16 months, and the median duration of response was 12 months.
Grade 3 adverse events included thrombocytopenia, fatigue,
peripheral neuropathy, and neutropenia [33]. This trial was
uncontrolled, however, several processes were in place to reduce
bias in analyzing response to therapy. Each patient was his or her
own control in the assessment of time to progression of disease
relative to that with the last therapy received before enrollment,
and an analysis was performed to elucidate an association between
response to bortezomib alone and survival. The median duration of
survival among patients who did not respond was 8 months and
was in the range expected. Response to bortezomib did not
correlate with many standard multiple myeloma prognostic
factors such as deletion of chromosome 13, a predictor for poor
outcome with conventional therapy. The time to progression with
bortezomib therapy increased by a factor of 2–4, compared with
the most recent therapy patients received before entering the trial.
Responses were associated with increased hemoglobin and
decreased transfusions, improved quality of life, and increased
normal immunoglobulins. In 2003, bortezomib (Velcade, PS-341)
was approved by the U.S. Food and Drug Administration (U.S. FDA)
for the treatment of refractory multiple myeloma. Bortezomib
slowed progression of myeloma bone disease. This beneﬁcial
impact of bortezomib on bone metabolism was not due to anti-
myeloma activity; bortezomib directly interferes with osteoclas-
togenesis and resorption and promotes osteoblast formation and
function.
A randomized, multicenter Phase 3 trial comparing bortezo-
mib with high-dose dexamethasone in relapsed multiple myelo-
ma patients was initiated [34]. In 2005, bortezomib received
regular approval from the U.S. FDA for the treatment of multiple
myeloma progressing after at least one prior therapy. The
approval was based on the large, comparative international
open-label Phase 3 trial that randomized 669 multiple myeloma
patients treated with at least one previous systemic regimen to
receive bortezomib or high-dose dexamethasone in which
bortezomib efﬁcacy and safety was clear. At the pre-planned
interim analysis, the independent data-monitoring committee
recommended that bortezomib be offered to all dexamethasone-
treated study patients because the time to disease progression
was 6.2 months in the bortezomib treatment arm compared with3.5 months in the dexamethasone arm. The overall response rate
(complete responses plus partial responses) with bortezomib was
38% compared with a dexamethasone overall response rate of 18%.
On June 23, 2008, the U.S. FDA approved bortezomib for the
treatment of patients with multiple myeloma as a ﬁrst-line
therapy for patients. In 2006, bortezomib was approved for
treatment of relapsed or refractory mantle cell lymphoma, and in
2014, bortezomib was approved for ﬁrst-line therapy of patients
with mantle cell lymphoma.
Bortezomib was the ﬁrst proteasome inhibitor approved for the
therapy of multiple myeloma. Although bortezomib was a great
step forward in the multiple myeloma treatment, a sub-population
of patients failed to respond to bortezomib and almost all patients
relapsed after brotezomib either as a single agent or when used in
combination. The positive clinical outcome of bortezomib treat-
ment in multiple myeloma patients provided impetus for the
discovery and development of next generation proteasome
inhibitors with improved efﬁcacy and safety [35,36].
Despite the great success of bortezomib, there are some
patients who do not respond to the drug or respond brieﬂy, then
relapse. Bortezomib reversibly inhibits the CT-like activity in the
proteasome b core particle. Mutations and/or over-expression of
b subunits is a frequent cause of bortezomib resistance. Point
mutations in PSMB5 of the b subunits are an important
mechanism of bortezomib resistance. Clonal sub-lines of the
HT-29 adenocarcinoma line made resistance to bortezomib in cell
culture were 30-fold resistant to bortezomib. Two novel and
distinct mutations in the b subunits were identiﬁed in the
botrezoimb resistant clones. One of these mutations has been
found in bortezomib-resistant multiple myeloma patients.
Proteasome activity and levels were increased in some bortezo-
mib-resistance clones. These changes correlated with a more
rapid recovery of proteasome activity following exposure to
bortezomib [37]. Modeling studies suggestion that the docu-
mented mutations decrease bortezomb binding afﬁnity resulting
in the decreased duration of inhibition of the CT-like activity by
bortezomib. Alterations in gene and/or protein expression in
stress, survival, and anti-apoptotic pathways are contributing
bortezomib resistance mechanisms [38].
3. Carﬁlzomib
Bortezomib success stimulated broad investigation of the
proteasome as an anticancer target. Carﬁlzomib (PR-171) is an
irreversible epoxyketone proteasome inhibitor. Carﬁlzomib is
chemically, structurally and mechanistically different from borte-
zomib. Carﬁlzomib is equally potent but more selective for the
chymotrypsin-like activity of the proteasome than bortezomib
(Fig. 3 and Table 1). In cell culture, carﬁlzomib is more cytotoxic
than bortezomib following brief treatments at the same concen-
tration under conditions that mimicked the pharmacokinetics of
both compounds. Hematologic tumor cells were most sensitive to
carﬁlzomib exposure, compared with solid tumor cells and non-
transformed cell types. Cellular consequences of carﬁlzomib
exposure included accumulation of proteasome substrates, induc-
tion of cell cycle arrest, and apoptosis. Carﬁlzomib administration
to mice resulted in dose-dependent inhibition of the chymotryp-
sin-like proteasome activity in all tissues examined except the
brain. Carﬁlzomib was well-tolerated in mice when administered
for 2 days at 5 mg/kg or for 5 days at 2 mg/kg These regimens
resulted in >80% proteasome inhibition in blood and most tissues.
Carﬁlzomib anticancer activity was both dose and schedule
dependent in human tumor xenograft models [39]. Proteasome
inhibition was longer with carﬁlzomib due to covalent bonding of
the compound to the target protein, than with bortezomib.
The carﬁlzomib epoxyketone pharmacophore is selective for the
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in each of the proteolytic active sites in the proteasome.
In a Phase 1 clinical trial, reported in 2009, assessing carﬁlzomib
safety and efﬁcacy in patients with relapsed or refractory
hematologic malignancies, 29 patients were enrolled who after
at least two prior therapies had relapsed or refractory disease.
Carﬁlzomib antitumor activity was observed at doses 11 mg/
m2. The Phase 1 carﬁlzomib clinical trial had one patient with
mantle cell lymphoma had an unconﬁrmed complete response,
one patient with multiple myeloma had a partial response, and one
patient with multiple myeloma and one patient with Walden-
stro¨m’s macroglobulinemia had minimal responses. Of, thus,
indicating that carﬁlzomib was tolerable and had clinical activity
in multiple hematologic malignancies [40]. In 2012, carﬁlzomib
was approved for the treatment of multiple myeloma patients who
have received at least two prior therapies including bortezomib
and an immunomodulatory agent [41].
4. Marizomib
Marizomib (NPI-0052, Salinosporamide A) is a naturally
occurring g-lactam-b-lactone bicyclic compound which is an
irreversible proteasome inhibitor. Marizomib inhibits all three
proteasome protease activities and is not cross-resistant with
bortezomib. In human multiple myeloma xenografts marizomib is
an active antitumor agent which is well tolerated, and extends
survival [42]. Chemically, marizomib has a leaving group, which
increases cytotoxic potency in RPMI 8226 multiple myeloma and
PC-3 prostate adenocarcinoma cells. Marizomib efﬂuxes slowly
from cells due to irreversible binding to the proteasome
[43]. Pharmacodynamic assay showed that marizomib is a potent
proteasome inhibitor and that in vivo proteasome inhibition is
dose, cycle and schedule dependent. Pharmacokinetic assay
indicated that marizomib has a short half-life with rapid clearance
and a large volume of distribution. Marizomib exposure increases
linearly with dose. In single agent Phase 1 trials, marizomib
administered on a day 1, 8, and 15 schedule was tolerated up to
0.4–0.6 mg/m2 [36]. In one Phase 1 trial which included 34 patients,
88% had received prior bortezomib, and 71% were refractory to
bortezomib. The marizomib MTD was 0.4 mg/m2 when adminis-
tered as a 60-minute intravenous infusion and 0.5 mg/m2 when
administered as a 120-minute intravenous infusion. Three of
15 patients treated in the active dose range achieved a PR
[44]. Marizomib is in Phase 1/2 clinical trial in relapsed or
refractory multiple myeloma and grade IV malignant glioma
(clinicaltrials.gov).
5. Ixazomib
Ixazomib (MLN9708/MLN2238), a novel orally bioactive
boronic acid proteasome inhibitor, was tested for activity against
in multiple myeloma using well-established in cell culture and in
tumor models [45]. Multiple myeloma cell lines, primary patient
cells, and a human multiple myeloma xenograft tumor model were
used in the initial study of MLN9708/MLN2238 antitumor activity.
MLN2238 inhibited the chymotrypsin-like activity of the protea-
some in multiple myeloma cells and induced accumulation of
multiply ubiquitinated proteins (Fig. 3 and Table 1). MLN2238
inhibited growth and caused apoptosis in multiple myeloma cells
resistant to conventional cytotoxic compounds and bortezomib
without affecting the viability of normal cells. In xenograft tumor
models, MLN2238 was well-tolerated and slowed tumor growth.
Comparison of MLN2238 and bortezomib in a tumor model
showed a longer survival time in mice treated with MLN2238 than
mice treated with bortezomib. Immuno-staining of multiple
myeloma xenograft tumors from MLN2238-treated mice elucidat-ed growth inhibition, apoptosis, and decreased angiogenesis.
Combining MLN2238 with lenalidomide, vorinostat, or dexameth-
asone increased cytotoxicity and anticancer activity [45].
Ixazomib (MLN9708/MLN2238) was the ﬁrst oral proteasome
inhibitor to be assessed for the treatment of multiple myeloma in
patients. Ixazomib had very different pharmacokinetic and
pharmacodynamic parameters than bortezomib, in addition to
similar efﬁcacy in multiple myeloma growth control and bone loss
prevention. Ixazomib was not cross-resistant with bortezomib.
Phase 1/2 clinical studies using ixazomib once weekly or twice
weekly in relapsed/refractory multiple myeloma patients sug-
gested single agent antitumor activity, however, promising clinical
results were obtained with the combination of ixazomib,
lenalidomide, and dexamethasone in newly diagnosed multiple
myeloma patients. Ixazomib has been tested in systemic amyloid-
osis as a single agent, showing important activity in this difﬁcult
plasma cell dyscrasia [46]. Clinical trials of orally administered
ixazomib (now in Phase 3) indicate that ixazomib is tolerable with
infrequent peripheral neuropathy and clinical anti-myeloma
activity either alone or in combination with other anti-myeloma
drugs with signs of additional beneﬁcial bone effects [47–49].
In a Phase 1 clinical trial, 60 patients with relapsed/refractory
multiple myeloma who had a median of 4 prior therapeutic
regimens including bortezomib, lenalidomide, thalidomide, and
carﬁlzomib and marizomib, received single-agent ixazomib on
days 1, 4, 8, and 11 in 21-day cycles. The maximum tolerated dose
was 2.0 mg/m2. Patients received a median of 4 cycles with a range
of 1–39. Eighteen percent of patients received 12 cycles. The
ixazomib terminal half-life was 3.3–7.4 days and the plasma
exposure increased proportionally with ixazomib dose. Among the
evaluable patients, 15% achieved a partial response and 76%
achieved stable disease [50]. Another Phase 1 trial enrolled
60 patients with relapsed, refractory multiple myeloma to evaluate
safety and tolerability and determine the maximum tolerated dose
of single agent, oral ixazomib administered weekly for 3 of
4 weeks. Upon maximum tolerated dose determination, patients
were enrolled to 4 different cohorts based on clinical status and
prior bortezomib and carﬁlzomib exposure. The ixazomib maxi-
mum tolerated dose was 2.97 mg/m2. Nine patients achieved a
partial response, including 8 evaluable patients treated at the MTD.
Pharmacokinetic studies indicated a long terminal half-life for the
compound of 3.6–11.3 days [51,52]. Ixazomib is currently in
multiple Phase 3 clinical trials.
6. Oprozomib
The novel proteasome irreversible inhibitor, oprozomib (ONX
0912) is a tripeptide epoxyketone and can be described as an orally
bioavailable analog of carﬁlzomib (Fig. 3 and Table 1). Oprozomib
inhibited growth and induced apoptosis in multiple myeloma cells
resistant to conventional therapy and bortezomib. Oprozomib
cytotoxicity was simultaneous with activation of caspase-8,
caspase-9, caspase-3, and poly(ADP) ribose polymerase. Oprozo-
mib inhibited of migration of multiple myeloma cells. Like
bortezomib, oprozomib, inhibited proteasome chymotrypsin-like
activity. In mouse tumor models, oprozomib inhibited tumor
progression and prolonged survival. Immuno-staining of multiple
myeloma tumors from oprozomib-treated mice showed apoptosis,
and decreased angiogenesis. Finally, oprozomib enhanced the
activity of bortezomib, lenalidomide, dexamethasone, and a pan-
histone deacetylase inhibitor [53]. Interactions between multiple
myeloma cells and the bone marrow microenvironment increased
the number and activity of bone-resorbing osteoclasts while
decreasing bone-forming osteoblasts resulting in increased tumor
growth and osteolytic lesions. At clinically relevant concentrations,
carﬁlzomib and oprozomib inhibited osteoclast formation and
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tion and matrix mineralization. Carﬁlzomib and oprozomib
increased trabecular bone volume, decreased bone resorption
and increased bone formation in non-tumor bearing mice. In
mouse bearing disseminated multiple myeloma, carﬁlzomib and
oprozomib decreased tumor burden and prevented bone loss
[53]. There is an on-going open-label Phase 1/2 study of the
efﬁcacy and safety of oprozomib hematologic malignancy patients
[54]. The objectives of Phase 1b were to determine oprozomib
maximum tolerated dose and the safety and tolerability. The
objective of the Phase 2 portion of the trial was to determine
the overall response rate. Oprozomib was administered once daily
on days 1, 2, 8, and 9 of a 14-day cycle or on days 1–5 of a 14-day
cycle. The starting dose was 150 mg/day and was increased to
330 mg/day. In the Phase 2 portion of the trial, the oprozomib dose
was 240 mg/day on days 1–5 of a 14-day cycle. In the Phase
2 portion of the trial using the days 1–5 schedule, the overall
response rate in carﬁlzomib-refractory patients and carﬁlzomib-
sensitive patients was 27.3% and the overall response rate among
bortezomib-refractory patients was 25.0% (clinical trials.gov)
[55].
7. Delanzomib
Delanzomib (CEP-18770) is an orally bioavailable inhibitor of
the proteasome chymotrypsin-like activity that decreases NF-kB
activity and the expression of several NF-kB downstream effectors
(Fig. 3 and Table 1). Delanzomib caused apoptotic cell death in
multiple myeloma cell lines and in puriﬁed CD138-positive
primary cells from untreated and bortezomib-treated multiple
myeloma patients. In culture, delanzomib had anti-angiogenic
activity and suppressed RANKL osteoclastogenesis. Delanzomib
was less cytotoxic toward normal human epithelial cells, bone
marrow progenitors, and bone marrow-derived stromal cells than
toward multiple myeloma cells. Delanzomib intravenous or oral
administration to mice resulted in a sustained pharmacodynamic
inhibition of proteasome activity in tumors relative to normal
tissues, and resulted in complete regression of multiple myeloma
xenografts and in a systemic model of multiple myeloma increased
median survival [56]. Delanzomib in combination with dexameth-
asone or lenalidomide resulted in longer tumor growth delays
compared to vehicle alone, each drug alone, or the dexamethasone
and lenalidomide doublet. The three xenograft studies suggested
that delanzomib in combination with dexamethasone and
lenalidomide may be useful for multiple myeloma treatment
[57]. Bortezomib and delanzomib were compared for proteasome
inhibitory activity using ﬂuorogenic substrates and a ﬂuorescent
proteasome activity probe. Bortezomib and delanzomib were
equipotent in inhibiting distinct subunits of the proteasome in a
panel of cell lines. In a multiple myeloma model, tumor
proteasome activity was inhibited to a greater extent by
delanzomib then by bortezomib. Delanzomib was not cross
resistant with bortezomib in vitro [58]. Oral or intravenous
delanzomib administration was evaluated in mice bearing
multiple myeloma tumors alone and in combination with
conventional therapeutics. Delanzomib combined with melphalan
or bortezomib resulted in synergistic inhibition of multiple
myeloma cell viability. In multiple myeloma xenografts, the
addition of intravenous delanzomib to melphalan prevented the
growth of melphalan-sensitive and melphalan-resistant tumors.
The combination of intravenous delanzomib and bortezomib
resulted in complete regression of bortezomib-sensitive tumors
and delayed progression of bortezomib-resistant tumors com-
pared with either agent alone. Single agent oral delanzomib
produced anti-multiple myeloma effects in the same xenograft
models [59].Delanzomib safety, pharmacokinetics and pharmacodynamics
of, were assessed after intravenous administration on days 1, 4,
8 and 11 of an every 21 days cycle in patients with solid tumors and
multiple myeloma. Thirty-eight patients were treated with
delanzomib at doses ranging from 0.1 to 1.8 mg/m2. The recom-
mended Phase 2 dose of 1.5 mg/m2 was tested in additional
patients. Delanzomib pharmacokinetics in plasma was linear with
a half-life of the elimination phase of 62.0  43.5 h. Proteasome
inhibition in peripheral blood mononuclear cells was dose related in
multiple myeloma patients [60]. Delanzomib has completed Phase
1 clinical trial (clinicaltrials.gov).
8. Other indications
There are no U.S. FDA approved treatment for patients affected
by the recessively inherited, progressive muscular dystrophies
caused by muscle membrane repair protein dysferlin deﬁciency.
Marked reduction in dysferlin in patients harboring missense
mutations implies that dysferlin is degraded by the cell quality
control machinery. Data suggest that missense mutated dysferlin
might be functional if salvaged from degradation by the protea-
some. Three patients with muscular dystrophy due to homozygous
mutation in dysferlin were treated with the proteasome inhibitor
bortezomib. Dysferlin expression was monitored in monocytes and
in skeletal muscle by biopsy. Expression of missense mutated
dysferlin in the skeletal muscle and monocytes of the three
patients increased, and dysferlin correctly localized to the
sarcolemma of muscle ﬁbers. Salvaged missense mutated dysferlin
was functional in patient-derived muscle cells treated with three
different proteasome inhibitors. Proteasome inhibition increased
expression of missense mutated dysferlin, suggesting that this
therapeutic strategy may beneﬁt patients with dysferlinopathies
and possibly other genetic diseases [61].
Late-stage systemic lupus erythematosus (SLE) is treated with
cytotoxic agents. Delanzomib was tested in comparison with
bortezomib to treat fatal lupus nephritis (LN) in mice. Age matched
mice with established SLE or LN, were treated with delanzomib or
with bortezomib. Reduction of speciﬁc anti-chromatin, dsDNA
antibody secreting cells and circulating antinuclear antibodies,
were observed following delanzomib treatment. Reductions in
pro-inﬂammatory cytokines were observed in delanzomib-treated
animals. Delanzomib treatment suppressed the development and
progression of renal tissue damage and extended the survival of ill
mice. Proteinuria was decreased and severity of renal histopathol-
ogies reduced relative to vehicle-treated nephritic mice. Delanzo-
mib treatment resulted in improved stabilization of disease [62].
9. Conclusion
Proteasome inhibitors are a recent addition to the anticancer
armentarium. While cancer was not the ﬁrst therapeutic target
disease for bortezomib, the potency and toxicity of the agent re-
focused bortezomib development into cancer. After such a shaky
beginning, bortezomib and a company NCI partnership, became a
breakthrough drug for treatment of multiple myeloma, a cancer
that had not seen a therapeutic improvement for many years. The
clinical and commercial successful of bortezomib stimulated
several ﬁrms to search for second-generation proteasome inhibi-
tors with improved therapeutic indices and oral bioavailability
compared with bortezomib. Bortezomib is a boronic acid requiring
intravenous administration while ixazomib and delanzomib are
boronic acids that are taken orally. Carﬁlzomib is an irreversible
epoxyketone requiring intravenous administration, while oprozo-
mib is an epoxyketone that is taken orally. These compounds are
generally very potent cytotoxics, all of which focus on blocking the
proteasome chymotrypsin-like protease. The focus on multiple
B.A. Teicher, J.E. Tomaszewski / Biochemical Pharmacology 96 (2015) 1–98myeloma came from astute clinical observations during early
bortezomib clinical trials. Thus, discovery and development of the
proteasome inhibitor class of anticancer agents has progressed
through a classic route of serendipity and scientiﬁc investigation.
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